Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.
2,325 questions in 216 reviews · Airways
current versionsNo studies 249 · 10.7%Ungraded 107 · 4.6%Very low 276 · 11.9%Low 751 · 32.3%Moderate 718 · 30.9%High 224 · 9.6%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
PAAP vs no PAAP Serious adverse events (including deaths). · adults with asthma Personalised asthma action plans for adults with asthma (2017) · Cochrane | OR 3.26 [0.33, 32.21] | 1 study · 125 participants | Very low |
PAAP vs no PAAP Quality of life, change from baseline in AQLQ. · adults with asthma Personalised asthma action plans for adults with asthma (2017) · Cochrane | no estimate extracted | 3 studies · 441 participants | Low |
PAAP vs no PAAP Exacerbation requiring OCS. · adults with asthma Personalised asthma action plans for adults with asthma (2017) · Cochrane | OR 1.45 [0.84, 2.48] | 3 studies · 1136 participants | Very low |
PAAP vs no PAAP Lung function, change from baseline in FEV1 (L). · adults with asthma Personalised asthma action plans for adults with asthma (2017) · Cochrane | no estimate extracted | 3 studies · 392 participants | Low |
PAAP vs no PAAP Days lost from work or study. · adults with asthma Personalised asthma action plans for adults with asthma (2017) · Cochrane | no estimate extracted | 1 study · 74 participants | Low |
PAAP plus education vs education alone Exacerbation requiring ED or hospitalisation. · adults with asthma Personalised asthma action plans for adults with asthma (2017) · Cochrane | OR 1.08 [0.27, 4.32] | 1 study · 70 participants | Very low |
PAAP plus education vs education alone Asthma control, change from baseline in ACQ score. · adults with asthma Personalised asthma action plans for adults with asthma (2017) · Cochrane | no estimate extracted | 1 study · 70 participants | Low |
Umeclidinium bromide vs placebo Number of participants with exacerbations requiring steroids, antibiotics, or both · people with chronic obstructive pulmonary disease (COPD) Umeclidinium bromide versus placebo for people with chronic obstructive pulmonary disease (COPD) (2017) · Cochrane | OR 0.61 [0.46, 0.8] | 4 studies · 1922 participants | High |
Umeclidinium bromide vs placebo Quality of life: number of participants with ≥ 4 units improvement in SGRQ total score · people with chronic obstructive pulmonary disease (COPD) Umeclidinium bromide versus placebo for people with chronic obstructive pulmonary disease (COPD) (2017) · Cochrane | OR 1.45 [1.16, 1.82] | 3 studies · 1397 participants | Moderate |
Umeclidinium bromide vs placebo Non‐fatal serious adverse events · people with chronic obstructive pulmonary disease (COPD) Umeclidinium bromide versus placebo for people with chronic obstructive pulmonary disease (COPD) (2017) · Cochrane | OR 1.33 [0.89, 2] | 4 studies · 1922 participants | Moderate |
Umeclidinium bromide vs placebo Number of participants with hospital admissions due to COPD exacerbation · people with chronic obstructive pulmonary disease (COPD) Umeclidinium bromide versus placebo for people with chronic obstructive pulmonary disease (COPD) (2017) · Cochrane | OR 0.86 [0.25, 2.92] | 4 studies · 1922 participants | Low |
Umeclidinium bromide vs placebo Number of participants with ≥ 1 unit improvement in TDI focal score · people with chronic obstructive pulmonary disease (COPD) Umeclidinium bromide versus placebo for people with chronic obstructive pulmonary disease (COPD) (2017) · Cochrane | OR 1.71 [1.37, 2.15] | 3 studies · 1441 participants | High |
Umeclidinium bromide vs placebo Change from baseline in trough FEV1 (L) · people with chronic obstructive pulmonary disease (COPD) Umeclidinium bromide versus placebo for people with chronic obstructive pulmonary disease (COPD) (2017) · Cochrane | no estimate extracted | 4 studies · 1381 participants | High |
Umeclidinium bromide vs placebo Adverse events (not including serious adverse events) · people with chronic obstructive pulmonary disease (COPD) Umeclidinium bromide versus placebo for people with chronic obstructive pulmonary disease (COPD) (2017) · Cochrane | OR 1.06 [0.85, 1.31] | 4 studies · 1922 participants | Moderate |
AeriSeal vs control % change from baseline in FEV1 · Participants suffering from chronic obstructive pulmonary disease Bronchoscopic lung volume reduction procedures for chronic obstructive pulmonary disease (2017) · Cochrane | no estimate extracted | 1 study · 34 participants | Low |
Airway bypass stents vs control Units SGRQ at end of · Participants suffering from chronic obstructive pulmonary disease Bronchoscopic lung volume reduction procedures for chronic obstructive pulmonary disease (2017) · Cochrane | no estimate extracted | 1 study · 350 participants | High |
Airway bypass stents vs control Change from baseline in lung function parameters other than FEV1 · Participants suffering from chronic obstructive pulmonary disease Bronchoscopic lung volume reduction procedures for chronic obstructive pulmonary disease (2017) · Cochrane | no estimate extracted | 1 study · 350 participants | High |
Airway bypass stents vs control Meters 6MWD at end of · Participants suffering from chronic obstructive pulmonary disease Bronchoscopic lung volume reduction procedures for chronic obstructive pulmonary disease (2017) · Cochrane | no estimate extracted | 1 study · 350 participants | Moderate |
Airway bypass stents vs control Adverse events at end of · Participants suffering from chronic obstructive pulmonary disease Bronchoscopic lung volume reduction procedures for chronic obstructive pulmonary disease (2017) · Cochrane | OR 1.33 [0.65, 2.73] | 1 study · 315 participants | Moderate |
Airway bypass stents vs control Cost effectiveness · Participants suffering from chronic obstructive pulmonary disease Bronchoscopic lung volume reduction procedures for chronic obstructive pulmonary disease (2017) · Cochrane | no estimate extracted | NR | No studies |
Endobronchial coils vs control % change from baseline in FEV1 · Participants suffering from chronic obstructive pulmonary disease Bronchoscopic lung volume reduction procedures for chronic obstructive pulmonary disease (2017) · Cochrane | no estimate extracted | 2 studies · 146 participants | Moderate |
Endobronchial coils vs control Mortality at end of · Participants suffering from chronic obstructive pulmonary disease Bronchoscopic lung volume reduction procedures for chronic obstructive pulmonary disease (2017) · Cochrane | OR 1.49 [0.67, 3.29] | 3 studies · 461 participants | Moderate |
Endobronchial coils vs control Units SGRQ change from baseline · Participants suffering from chronic obstructive pulmonary disease Bronchoscopic lung volume reduction procedures for chronic obstructive pulmonary disease (2017) · Cochrane | no estimate extracted | 3 studies · 461 participants | Moderate |
Endobronchial coils vs control Change from baseline in lung function parameters other than FEV1 · Participants suffering from chronic obstructive pulmonary disease Bronchoscopic lung volume reduction procedures for chronic obstructive pulmonary disease (2017) · Cochrane | no estimate extracted | 3 studies · 461 participants | High |
Endobronchial coils vs control Meters change from baseline in 6MWD · Participants suffering from chronic obstructive pulmonary disease Bronchoscopic lung volume reduction procedures for chronic obstructive pulmonary disease (2017) · Cochrane | no estimate extracted | 3 studies · 461 participants | Low |
AeriSeal vs control Mortality at end of · Participants suffering from chronic obstructive pulmonary disease Bronchoscopic lung volume reduction procedures for chronic obstructive pulmonary disease (2017) · Cochrane | OR 2.9 [0.14, 62.15] | 1 study · 95 participants | Low |
Endobronchial coils vs control Adverse events at end of · Participants suffering from chronic obstructive pulmonary disease Bronchoscopic lung volume reduction procedures for chronic obstructive pulmonary disease (2017) · Cochrane | OR 2.14 [1.41, 3.23] | 3 studies · 461 participants | High |
Endobronchial coils vs control Cost effectiveness at end of · Participants suffering from chronic obstructive pulmonary disease Bronchoscopic lung volume reduction procedures for chronic obstructive pulmonary disease (2017) · Cochrane | no estimate extracted | NR | Moderate |
Endobronchial valves vs control % change from baseline in FEV1 · Participants suffering from chronic obstructive pulmonary disease Bronchoscopic lung volume reduction procedures for chronic obstructive pulmonary disease (2017) · Cochrane | no estimate extracted | 5 studies · 703 participants | Low |
Endobronchial valves vs control Mortality at end of · Participants suffering from chronic obstructive pulmonary disease Bronchoscopic lung volume reduction procedures for chronic obstructive pulmonary disease (2017) · Cochrane | OR 1.07 [0.47, 2.43] | 5 studies · 703 participants | Moderate |
Endobronchial valves vs control Units of SGRQ change from baseline · Participants suffering from chronic obstructive pulmonary disease Bronchoscopic lung volume reduction procedures for chronic obstructive pulmonary disease (2017) · Cochrane | no estimate extracted | 5 studies · 695 participants | Low |
Endobronchial valves vs control Change from baseline in lung function parameters other than FEV1 · Participants suffering from chronic obstructive pulmonary disease Bronchoscopic lung volume reduction procedures for chronic obstructive pulmonary disease (2017) · Cochrane | no estimate extracted | 3 studies · 200 participants | Moderate |
Endobronchial valves vs control Meters change from baseline in 6MWD · Participants suffering from chronic obstructive pulmonary disease Bronchoscopic lung volume reduction procedures for chronic obstructive pulmonary disease (2017) · Cochrane | no estimate extracted | 4 studies · 379 participants | Low |
Endobronchial valves vs control Adverse events at end of · Participants suffering from chronic obstructive pulmonary disease Bronchoscopic lung volume reduction procedures for chronic obstructive pulmonary disease (2017) · Cochrane | OR 5.85 [2.16, 15.84] | 3 studies · 482 participants | High |
Endobronchial valves vs control Cost‐ effectiveness · Participants suffering from chronic obstructive pulmonary disease Bronchoscopic lung volume reduction procedures for chronic obstructive pulmonary disease (2017) · Cochrane | no estimate extracted | NR | Moderate |
Intrabronchial valves vs control % change from baseline in FEV1 · Participants suffering from chronic obstructive pulmonary disease Bronchoscopic lung volume reduction procedures for chronic obstructive pulmonary disease (2017) · Cochrane | no estimate extracted | 1 study · 272 participants | Moderate |
AeriSeal vs control Units SGRQ change from baseline · Participants suffering from chronic obstructive pulmonary disease Bronchoscopic lung volume reduction procedures for chronic obstructive pulmonary disease (2017) · Cochrane | no estimate extracted | 1 study · 34 participants | Low |
Intrabronchial valves vs control Mortality at end of · Participants suffering from chronic obstructive pulmonary disease Bronchoscopic lung volume reduction procedures for chronic obstructive pulmonary disease (2017) · Cochrane | OR 4.95 [0.85, 28.94] | 2 studies · 350 participants | Moderate |
Intrabronchial valves vs control Units of SGRQ change from baseline · Participants suffering from chronic obstructive pulmonary disease Bronchoscopic lung volume reduction procedures for chronic obstructive pulmonary disease (2017) · Cochrane | no estimate extracted | 2 studies · 350 participants | High |
Intrabronchial valves vs control Change from baseline in lung function parameters other than FEV1 · Participants suffering from chronic obstructive pulmonary disease Bronchoscopic lung volume reduction procedures for chronic obstructive pulmonary disease (2017) · Cochrane | no estimate extracted | 2 studies · 312 participants | High |
Intrabronchial valves vs control Meters change from baseline in 6MWD · Participants suffering from chronic obstructive pulmonary disease Bronchoscopic lung volume reduction procedures for chronic obstructive pulmonary disease (2017) · Cochrane | no estimate extracted | 2 studies · 316 participants | Moderate |
Intrabronchial valves vs control Adverse events at end of · Participants suffering from chronic obstructive pulmonary disease Bronchoscopic lung volume reduction procedures for chronic obstructive pulmonary disease (2017) · Cochrane | OR 3.41 [1.48, 7.84] | 2 studies · 350 participants | High |
Intrabronchial valves vs control Cost‐ effectiveness · Participants suffering from chronic obstructive pulmonary disease Bronchoscopic lung volume reduction procedures for chronic obstructive pulmonary disease (2017) · Cochrane | no estimate extracted | NR | No studies |
Vapour ablation vs control % change from baseline in FEV1 · Participants suffering from chronic obstructive pulmonary disease Bronchoscopic lung volume reduction procedures for chronic obstructive pulmonary disease (2017) · Cochrane | no estimate extracted | 1 study · 64 participants | Moderate |
Vapour ablation vs control Mortality at end of · Participants suffering from chronic obstructive pulmonary disease Bronchoscopic lung volume reduction procedures for chronic obstructive pulmonary disease (2017) · Cochrane | OR 2.82 [0.13, 61.06] | 1 study · 69 participants | Low |
Vapour ablation vs control Units of SGRQ change from baseline · Participants suffering from chronic obstructive pulmonary disease Bronchoscopic lung volume reduction procedures for chronic obstructive pulmonary disease (2017) · Cochrane | no estimate extracted | 1 study · 65 participants | Low |
Vapour ablation vs control Lung function parameters other than FEV1 · Participants suffering from chronic obstructive pulmonary disease Bronchoscopic lung volume reduction procedures for chronic obstructive pulmonary disease (2017) · Cochrane | no estimate extracted | 1 study · 69 participants | Moderate |
AeriSeal vs control Change from baseline in lung function parameters other than FEV1 · Participants suffering from chronic obstructive pulmonary disease Bronchoscopic lung volume reduction procedures for chronic obstructive pulmonary disease (2017) · Cochrane | no estimate extracted | NR | No studies |
Vapour ablation vs control Meters at end of · Participants suffering from chronic obstructive pulmonary disease Bronchoscopic lung volume reduction procedures for chronic obstructive pulmonary disease (2017) · Cochrane | no estimate extracted | 1 study · 69 participants | Low |
Vapour ablation vs control Adverse events at end of · Participants suffering from chronic obstructive pulmonary disease Bronchoscopic lung volume reduction procedures for chronic obstructive pulmonary disease (2017) · Cochrane | OR 3.86 [1, 14.97] | 1 study · 69 participants | Moderate |